U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891365) titled 'Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases' on March 17.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which cannot be prescribed by doctors. Th...